Biopharmaceutical company Code Pharma has announced highly encouraging outcomes in the development of its innovative HIV treatment, Gammora. In a recent clinical trial, Gammora demonstrated a significant reduction in viral load, with some patients achieving undetectable levels of the virus.
Gammora’s success aligns with Code Pharma’s mission to develop transformative therapies for global health challenges. The company is now focused on advancing its clinical studies and working toward regulatory approvals.